MAIA Biotechnology, Inc.: Business Overview, Financials & Competitive Analysis
MAIA Biotechnology, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). High-risk, early-stage immuno-oncology play with first-in-class mechanism targeting $50B+ market, dependent entirely on Phase 3 trial outcomes. Early-stage clinical company with innovative telomere-targeting approach and FDA Fast Track designation demonstrates strong science, but pre-revenue status, minimal market capitalization (~$41.5M as of November 2025), and dependence on Phase 3 trial.
What is MAIA Biotechnology, Inc.'s industry? MAIA Biotechnology, Inc. (maiabiotech.com) operates in Biopharmaceuticals / Immuno-Oncology. AskCyborg classifies MAIA Biotechnology, Inc. under Biopharmaceuticals / Immuno-Oncology in its company registry.
MAIA Biotechnology is an immuno-oncology company focused on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. The c...
Cyborg Score thesis
High-risk, early-stage immuno-oncology play with first-in-class mechanism targeting $50B+ market, dependent entirely on Phase 3...
Read the full analyst-debate transcript →Get the Latest MAIA Biotechnology, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMAIA Biotechnology, Inc. Overview
Pro stress-test →MAIA Biotechnology is an immuno-oncology company focused on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. The company's lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Strategic Profile
Pro stress-test →THIO is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity, with patients with advanced NSCLC treated first with THIO followed by the immune checkpoint inhibitor Libtayo. The company has received FDA's Fast Track Designation for Ateganosine as a treatment for Non-Small Cell Lung Cancer, positioning it for accelerated development in a major oncology market.
Competitive Landscape
Pro stress-test →Competitors include Candel Therapeutics, Agenus, BioAtla, Black Diamond Therapeutics, and Pyxis Oncology in the immuno-oncology space. MAIA's differentiation lies in its telomere-targeting mechanism of action, which represents a novel approach to immunotherapy compared to established checkpoint inhibitor companies.
Industry Context
MAIA Biotechnology, Inc. operates in Biopharmaceuticals / Immuno-Oncology.
Key facts
Founded: 2018 · Headquarters: Chicago, Illinois · Market cap: $41.5M